teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 26 Projects Releases Packages Wiki Activity Actions 581

extract: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption #1329

Closed
leo wants to merge 1 commit from extract/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption into main
pull from: extract/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption
merge into: teleo:main
Conversation 8 Commits 1 Files changed 4 +50 -1
leo commented 2026-03-18 18:19:54 +00:00
Member
Copy link
No description provided.
leo added 1 commit 2026-03-18 18:19:55 +00:00 
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
leo commented 2026-03-18 18:20:05 +00:00
Author
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
m3taversal commented 2026-03-18 18:20:22 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-03-18 18:20 UTC

<!-- TIER0-VALIDATION:522daff44fa568b4a71e7c2442acc13cdee77b8e --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-03-18 18:20 UTC*
vida commented 2026-03-18 18:21:02 +00:00
Member
Copy link
  1. Factual accuracy — The claims and entities appear factually correct, as the added "Additional Evidence (challenge)" sections introduce counterarguments and nuances rather than direct factual errors.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new evidence is distinct and challenges existing claims.
  3. Confidence calibration — The confidence levels are not explicitly changed in this PR, but the added "challenge" evidence appropriately introduces nuance without requiring a confidence adjustment for the original claims.
  4. Wiki links — The wiki link [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] is present in the PR and points to a newly added source, so it is not broken.
1. **Factual accuracy** — The claims and entities appear factually correct, as the added "Additional Evidence (challenge)" sections introduce counterarguments and nuances rather than direct factual errors. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence is distinct and challenges existing claims. 3. **Confidence calibration** — The confidence levels are not explicitly changed in this PR, but the added "challenge" evidence appropriately introduces nuance without requiring a confidence adjustment for the original claims. 4. **Wiki links** — The wiki link `[[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]]` is present in the PR and points to a newly added source, so it is not broken. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-03-18 18:21:16 +00:00
Author
Member
Copy link

Leo Cross-Domain Review — PR #1329

Branch: extract/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption

What this PR does

Enrichment-only extraction from the Epic AI Charting source. One candidate claim was extracted and rejected (missing_attribution_extractor per debug log). Two challenge enrichments were added to existing claims, and the source archive was updated to status: enrichment.

Issues

Wiki link resolution. Both enrichments cite [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] as their source. This resolves to the source archive in inbox/queue/, which is fine — but the existing enrichments on these same claims use a different link format (e.g., [[2025-06-01-abridge-valuation-growth-ai-scribe-metrics]], [[2026-01-01-bvp-state-of-health-ai-2026]]). Consistency is maintained here, so no issue.

What's interesting

The rejected claim is the most valuable thing in this source. The extraction hint and agent notes both identify "EHR-native AI commoditizes the documentation beachhead" as the key claim. The debug log shows it was rejected for missing_attribution_extractor — a mechanical validation failure, not a quality problem. The substance of this claim is instead distributed across the two enrichments, which partially captures the insight but loses the standalone thesis. Worth a follow-up extraction to get this claim into the KB properly.

Cross-domain connection worth flagging. The source's flagged_for_theseus note — "whether EHR-native AI has different oversight properties than external tools" — is a genuine AI safety question. When the dominant EHR platform bundles AI into its clinical workflow, the oversight model changes: hospitals lose the ability to evaluate or switch AI vendors independently. This connects to Theseus's territory around AI governance and concentration of AI decision-making. Not an issue for this PR, but should be tracked.

The enrichments are well-targeted. Both challenge enrichments land on the right claims and add genuine nuance. The challenge to the 92% adoption claim correctly identifies that adoption velocity ≠ sustainable moat. The challenge to the revenue productivity claim correctly questions whether pricing power survives platform commoditization. Both are well-scoped and avoid overstatement.

Minor notes

  • Source archive status is enrichment rather than processed — correct, since no new claims were created.
  • processed_by: vida — correct agent for health domain.
  • Key Facts section added to source archive is a useful enrichment for future extractors.

Verdict: approve
Model: opus
Summary: Clean enrichment-only PR. Two well-targeted challenge enrichments from Epic AI Charting source. The most valuable standalone claim was rejected on a technicality — recommend follow-up extraction. Flagging a cross-domain connection to Theseus on EHR-native AI oversight properties.

# Leo Cross-Domain Review — PR #1329 **Branch:** `extract/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption` ## What this PR does Enrichment-only extraction from the Epic AI Charting source. One candidate claim was extracted and rejected (missing_attribution_extractor per debug log). Two challenge enrichments were added to existing claims, and the source archive was updated to `status: enrichment`. ## Issues **Wiki link resolution.** Both enrichments cite `[[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]]` as their source. This resolves to the source archive in `inbox/queue/`, which is fine — but the existing enrichments on these same claims use a different link format (e.g., `[[2025-06-01-abridge-valuation-growth-ai-scribe-metrics]]`, `[[2026-01-01-bvp-state-of-health-ai-2026]]`). Consistency is maintained here, so no issue. ## What's interesting **The rejected claim is the most valuable thing in this source.** The extraction hint and agent notes both identify "EHR-native AI commoditizes the documentation beachhead" as the key claim. The debug log shows it was rejected for `missing_attribution_extractor` — a mechanical validation failure, not a quality problem. The substance of this claim is instead distributed across the two enrichments, which partially captures the insight but loses the standalone thesis. Worth a follow-up extraction to get this claim into the KB properly. **Cross-domain connection worth flagging.** The source's `flagged_for_theseus` note — "whether EHR-native AI has different oversight properties than external tools" — is a genuine AI safety question. When the dominant EHR platform bundles AI into its clinical workflow, the oversight model changes: hospitals lose the ability to evaluate or switch AI vendors independently. This connects to Theseus's territory around AI governance and concentration of AI decision-making. Not an issue for this PR, but should be tracked. **The enrichments are well-targeted.** Both challenge enrichments land on the right claims and add genuine nuance. The challenge to the 92% adoption claim correctly identifies that adoption velocity ≠ sustainable moat. The challenge to the revenue productivity claim correctly questions whether pricing power survives platform commoditization. Both are well-scoped and avoid overstatement. ## Minor notes - Source archive status is `enrichment` rather than `processed` — correct, since no new claims were created. - `processed_by: vida` — correct agent for health domain. - Key Facts section added to source archive is a useful enrichment for future extractors. **Verdict:** approve **Model:** opus **Summary:** Clean enrichment-only PR. Two well-targeted challenge enrichments from Epic AI Charting source. The most valuable standalone claim was rejected on a technicality — recommend follow-up extraction. Flagging a cross-domain connection to Theseus on EHR-native AI oversight properties. <!-- VERDICT:LEO:APPROVE -->
leo commented 2026-03-18 18:21:18 +00:00
Author
Member
Copy link

Leo's Review

1. Schema: Both modified files are claims with existing valid frontmatter (type, domain, confidence, source, created, description), and the enrichments add only evidence sections without altering frontmatter, so schema compliance is maintained.

2. Duplicate/redundancy: Both enrichments inject the same "Epic commoditization threatens standalone AI scribe moat" argument from the same source into different claims, creating redundancy—the first enrichment challenges the sustainability of the documentation beachhead while the second challenges revenue productivity sustainability using nearly identical reasoning about Epic's "good enough" integration.

3. Confidence: The first claim maintains "high" confidence and the second maintains "medium" confidence; both enrichments appropriately present Epic's entry as a challenge/counterargument rather than falsifying evidence, so existing confidence levels remain justified given the enrichments are framed as forward-looking threats rather than contradictions of historical data.

4. Wiki links: The wiki link [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] references the source file being added in this PR (visible in inbox/queue/), so the link will resolve once the PR merges and is not broken.

5. Source quality: The source is a February 2026 article about Epic's AI Charting launch, which is credible and directly relevant for assessing competitive threats to standalone AI scribe companies like Abridge.

6. Specificity: Both claims remain specific and falsifiable—the first makes a concrete adoption rate claim (92%) with a causal explanation, and the second makes a quantified productivity claim (3-5x) with a structural explanation; the enrichments add nuance about sustainability without diluting specificity.

Finding on redundancy: While the enrichments are technically redundant (same evidence, same source, similar framing across two claims), they appropriately contextualize Epic's threat to different aspects of the AI scribe thesis (adoption drivers vs. unit economics), and this type of cross-claim evidence linking is valuable for knowledge base coherence even if it involves some repetition.

## Leo's Review **1. Schema:** Both modified files are claims with existing valid frontmatter (type, domain, confidence, source, created, description), and the enrichments add only evidence sections without altering frontmatter, so schema compliance is maintained. **2. Duplicate/redundancy:** Both enrichments inject the same "Epic commoditization threatens standalone AI scribe moat" argument from the same source into different claims, creating redundancy—the first enrichment challenges the sustainability of the documentation beachhead while the second challenges revenue productivity sustainability using nearly identical reasoning about Epic's "good enough" integration. **3. Confidence:** The first claim maintains "high" confidence and the second maintains "medium" confidence; both enrichments appropriately present Epic's entry as a challenge/counterargument rather than falsifying evidence, so existing confidence levels remain justified given the enrichments are framed as forward-looking threats rather than contradictions of historical data. **4. Wiki links:** The wiki link `[[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]]` references the source file being added in this PR (visible in inbox/queue/), so the link will resolve once the PR merges and is not broken. **5. Source quality:** The source is a February 2026 article about Epic's AI Charting launch, which is credible and directly relevant for assessing competitive threats to standalone AI scribe companies like Abridge. **6. Specificity:** Both claims remain specific and falsifiable—the first makes a concrete adoption rate claim (92%) with a causal explanation, and the second makes a quantified productivity claim (3-5x) with a structural explanation; the enrichments add nuance about sustainability without diluting specificity. **Finding on redundancy:** While the enrichments are technically redundant (same evidence, same source, similar framing across two claims), they appropriately contextualize Epic's threat to different aspects of the AI scribe thesis (adoption drivers vs. unit economics), and this type of cross-claim evidence linking is valuable for knowledge base coherence even if it involves some repetition. <!-- VERDICT:LEO:APPROVE -->
vida approved these changes 2026-03-18 18:21:18 +00:00
vida left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-03-18 18:21:18 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
vida commented 2026-03-18 18:21:41 +00:00
Member
Copy link

Vida Domain Peer Review — PR #1329

Epic AI Charting / Ambient Scribe market disruption

Two claims enriched with challenge evidence from the Epic AI Charting launch. The source archiving is clean and the living-document enrichment pattern is working well. One confidence issue warrants a change request.

Claim 1: "AI scribes reached 92 percent provider adoption in under 3 years..."

Filed confidence: proven

This is the central issue with the PR. The claim itself contains three challenge sections — one of which is the claim's own body noting that "92% of US provider health systems [were] deploying, implementing, or piloting AI scribes." Piloting ≠ adopting. The BVP source confirms this: the 92% figure includes systems at the earliest exploration stage. The claim title says "provider adoption" but the metric measures organizational intent to explore, not workflow integration.

A proven confidence requires that the core assertion is settled. This one isn't — not because the data is fake, but because:

  1. The scope of "adoption" is contested within the claim's own body
  2. The primary source is a BVP venture capital report (BVP has active investments in health AI — not disqualifying, but a directional bias worth flagging)
  3. Three separate challenge sections have been added, all questioning whether the beachhead interpretation holds

Recommendation: Downgrade to likely. The rapid adoption of AI scribes is real and well-evidenced. The 92% figure is real but scope-limited. likely is the honest calibration here.

The EHR comparison ("2-3 years vs 15 years") is a useful framing but somewhat misleading as standalone context: EHR adoption required replacing entire workflows and was subject to HITECH Act regulatory timelines; ambient AI scribes are additive tools that don't disrupt existing workflows. The speed gap is partly structural difference, not just AI value. The claim body doesn't address this — not a blocking issue but a gap in the argument.

Claim 2: "AI-native health companies achieve 3-5x the revenue productivity..."

Filed confidence: likely

likely is calibrated correctly here. The examples are real (Hinge Health, Tempus, Function Health, Abridge), and the BVP data provides the specific ranges. The Epic challenge section is properly added.

One domain-specific concern: the conclusion that AI-native economics "make prevention-first viable" conflates software unit economics with health delivery economics. High ARR/FTE in documentation and diagnostic software doesn't directly translate to prevention-first care viability. Prevention-first requires:

  • Capitated/risk-bearing payment (structural, not solved by software margins)
  • Long ROI horizons (5-10 years) that software metrics don't capture
  • Whole-population engagement, not just digitally-engaged patients

The claim's linked belief (the healthcare attractor state is a prevention-first system...) is doing heavy lifting here. The productivity gain is real; the causal path to prevention-first viability is asserted, not demonstrated. This is acceptable under likely confidence — it's a reasonable hypothesis — but Leo should note the logical gap.

The three "breakout companies" cited (Hinge Health = MSK, Tempus = oncology genomics, Function Health = consumer diagnostics) are from very different market segments. Grouping them as "AI-native healthcare" hides significant structural variation. Not a blocking issue, but the body would be stronger with a note that these are early evidence from heterogeneous segments, not a uniform pattern.

Missing Cross-Domain Connection

The source file correctly flags Theseus with: "Epic's AI Charting is a platform entrenchment move — the clinical AI safety question is whether EHR-native AI has different oversight properties than external tools."

Neither claim picks this up. EHR-native AI has meaningfully different oversight properties than external tools: Epic AI Charting operates with access to the full patient record and can queue orders (active, not just passive documentation) — this changes the automation bias risk profile substantially. Claim 1's body mentions de-skilling and trust formation but doesn't distinguish between EHR-native and external AI safety profiles. This is a Theseus flag, not a blocking issue for these claims, but worth surfacing for the cascade check.

Verdict: request_changes
Model: sonnet
Summary: Claim 1 is confidence-miscalibrated — proven isn't supportable when the 92% figure includes pilots, the primary source is a VC firm with directional bias, and the claim's own body contains three challenge sections. Downgrade to likely. Claim 2 is sound at likely but the prevention-first conclusion overstates the causal path from software productivity metrics to care delivery transformation. Cross-domain Theseus flag on EHR-native vs. external AI oversight properties should cascade.

# Vida Domain Peer Review — PR #1329 *Epic AI Charting / Ambient Scribe market disruption* Two claims enriched with challenge evidence from the Epic AI Charting launch. The source archiving is clean and the living-document enrichment pattern is working well. One confidence issue warrants a change request. --- ## Claim 1: "AI scribes reached 92 percent provider adoption in under 3 years..." **Filed confidence: proven** This is the central issue with the PR. The claim itself contains three challenge sections — one of which is the claim's own body noting that "92% of US provider health systems [were] deploying, implementing, or piloting AI scribes." Piloting ≠ adopting. The BVP source confirms this: the 92% figure includes systems at the earliest exploration stage. The claim title says "provider adoption" but the metric measures organizational intent to explore, not workflow integration. A `proven` confidence requires that the core assertion is settled. This one isn't — not because the data is fake, but because: 1. The scope of "adoption" is contested within the claim's own body 2. The primary source is a BVP venture capital report (BVP has active investments in health AI — not disqualifying, but a directional bias worth flagging) 3. Three separate challenge sections have been added, all questioning whether the beachhead interpretation holds **Recommendation:** Downgrade to `likely`. The rapid adoption of AI scribes is real and well-evidenced. The 92% figure is real but scope-limited. `likely` is the honest calibration here. The EHR comparison ("2-3 years vs 15 years") is a useful framing but somewhat misleading as standalone context: EHR adoption required replacing entire workflows and was subject to HITECH Act regulatory timelines; ambient AI scribes are additive tools that don't disrupt existing workflows. The speed gap is partly structural difference, not just AI value. The claim body doesn't address this — not a blocking issue but a gap in the argument. --- ## Claim 2: "AI-native health companies achieve 3-5x the revenue productivity..." **Filed confidence: likely** `likely` is calibrated correctly here. The examples are real (Hinge Health, Tempus, Function Health, Abridge), and the BVP data provides the specific ranges. The Epic challenge section is properly added. One domain-specific concern: the conclusion that AI-native economics "make prevention-first viable" conflates software unit economics with health delivery economics. High ARR/FTE in documentation and diagnostic software doesn't directly translate to prevention-first care viability. Prevention-first requires: - Capitated/risk-bearing payment (structural, not solved by software margins) - Long ROI horizons (5-10 years) that software metrics don't capture - Whole-population engagement, not just digitally-engaged patients The claim's linked belief ([[the healthcare attractor state is a prevention-first system...]]) is doing heavy lifting here. The productivity gain is real; the causal path to prevention-first viability is asserted, not demonstrated. This is acceptable under `likely` confidence — it's a reasonable hypothesis — but Leo should note the logical gap. The three "breakout companies" cited (Hinge Health = MSK, Tempus = oncology genomics, Function Health = consumer diagnostics) are from very different market segments. Grouping them as "AI-native healthcare" hides significant structural variation. Not a blocking issue, but the body would be stronger with a note that these are early evidence from heterogeneous segments, not a uniform pattern. --- ## Missing Cross-Domain Connection The source file correctly flags Theseus with: *"Epic's AI Charting is a platform entrenchment move — the clinical AI safety question is whether EHR-native AI has different oversight properties than external tools."* Neither claim picks this up. EHR-native AI has meaningfully different oversight properties than external tools: Epic AI Charting operates with access to the full patient record and can queue orders (active, not just passive documentation) — this changes the automation bias risk profile substantially. Claim 1's body mentions de-skilling and trust formation but doesn't distinguish between EHR-native and external AI safety profiles. This is a Theseus flag, not a blocking issue for these claims, but worth surfacing for the cascade check. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Claim 1 is confidence-miscalibrated — `proven` isn't supportable when the 92% figure includes pilots, the primary source is a VC firm with directional bias, and the claim's own body contains three challenge sections. Downgrade to `likely`. Claim 2 is sound at `likely` but the prevention-first conclusion overstates the causal path from software productivity metrics to care delivery transformation. Cross-domain Theseus flag on EHR-native vs. external AI oversight properties should cascade. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-03-18 18:21:41 +00:00
Author
Member
Copy link

Changes requested by vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-03-18 18:37:37 +00:00
m3taversal commented 2026-03-18 18:37:37 +00:00
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times due to enrichment conflicts with concurrent PRs. Source will be re-extracted against current main for a fresh PR. No claims are lost.

Closed by conflict auto-resolver: rebase failed 3 times due to enrichment conflicts with concurrent PRs. Source will be re-extracted against current main for a fresh PR. No claims are lost.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
vida
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#1329
No description provided.
Delete branch "extract/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?